key: cord-0731158-jfdsagfw authors: Tousoulis, Dimitris title: Diabetes mellitus: Lessons from the COVID-19 pandemic date: 2020-05-18 journal: Hellenic J Cardiol DOI: 10.1016/j.hjc.2020.03.009 sha: 2c3ecb10697b48fa051d4e1f0fc4da5951300047 doc_id: 731158 cord_uid: jfdsagfw nan Wuhan (Hubei Province, China) [1] as an acute respiratory disease with variable severity caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) [2, 3] . At the end of January 2020, the World Health Organization (WHO) announced the COVID-19 outbreak a Public Health Emergency of International Concern. During February 2020, the daily number of new cases and new death increased worldwide including Europe. Accordingly, COVID-19 has been declared as a pandemic by WHO [4] . Beyond lung which is the primary affected organ cardiovascular system involvement has been also observed as the second most significant target of COVID-19 [5] . To this point the role of human angiotensin-converting enzyme 2 (ACE2) receptor which is bound with the SARS-CoV-2 viral surface spike protein facilitating virus entry into the cells [6] is of importance. ACE2 is expressed in the lung, mainly at type II alveolar cells, as well as in the myocardium, kidney, liver, intestinal epithelium, and vascular endothelium. Indeed COVID-19 cause multi-organ insufficiency or failure [7] . In patients with COVID-19 incidence of myocardial injury is estimated to 28% and is associated with fatal outcome [8] (Table 1) . From COVID-19 patients who dies, 75% has one or more comorbidities with hypertension recognized as the most common while risk factors associated with cardiovascular disease (CVD) i.e. diabetes mellitus, smoking, stroke has also been associated with fatal outcome [9] . Indeed, in patients with severe course of the COVID-19 with life threatening pneumonia in need of non-invasive or invasive ventilation the incidence of diabetes mellitus was more than 16%. The interaction between diabetes mellitus, COVID-19 pandemic and cardiovascular complications once again underline the point that cardiovascular system and diabetes mellitus should be studied and manage as one entity to achieve the best health outcome [10] [11] [12] [13] [14] [15] [16] . To this direction Tentolouris A et al. published in this issue of HJC significant data concerning the prevalence of diabetes mellitus in Greece [17] . Based on data on more than 30,000 subjects they reported an incidence of diabetes mellitus of 6.6%. Importantly, subjects with diabetes mellitus have increase prevalence of comorbidities including heart (24%), lung (11%) and kidney (3.4%) diseases. These interesting data on the comorbidities of subjects with diabetes mellitus provide clues to the reasons associated with worse outcome of COVID-19. Additionally, may help to identify the part of the population most vulnerable to disease for SARS-CoV-2. A few other interesting topics are covered in this issue of HJC. Pulmonary arterial hypertension despite recent advancements continue to pose significant difficulties in the diagnosis and treatment [18] [19] [20] [21] [22] . Echocardiography is the diagnostic modality most often used to raise the suspicion of pulmonary arterial hypertension which should be further confirmed by right heart catheterization. Tang P. [23] based on 30 subjects with pulmonary arterial hypertension reported that circulating expression levels of microRNAs-509-3p was significant lower compared to controls. Interestingly he concludes that expression levels of microRNAs-509-3p can be used as an additive to echocardiography diagnostic modality of pulmonary arterial hypertension facilitating the diagnostic approach and increasing the diagnostic efficacy of noninvasive modalities. In this issue of HJC Keramida K et al. [24] review the current literature on the role of right ventricle in patients with Hypertrophic cardiomyopathy [25] . Based on the current literature they focus on the remodeling of the right ventricle which may present with dynamic obstruction, subtle systolic impairment, and significant diastolic dysfunction. Importantly they emphasize the increase incidence of supraventricular and ventricular arrhythmias in subjects with hypertrophic cardiomyopathy and right ventricle involvement. To another interesting topic Andreou I et al. [26] review the evidence regarding the role of ongoing atherosclerosis on the incidence of stent failure. Specifically, they highlight that beyond neointimal growth or mechanical/technical complications responsible for early restenosis, recurrent atherosclerosis complications (i.e., due to neoatherosclerosis or paleoatherosclerosis), occurring inside or behind the stent is the reason of most stent complications. This data emphasizes the need to further study and manage atherosclerotic risk factors in patients following percutaneous transluminal interventions. To the management of coronary atherosclerotis Sandoval Y et al. [27] present their experience on the use of laser assisted orbital and rotational atherectomy. Specifically, they described how laser may modify the lesion to allow crossing when smaller balloons and microcatheters are unable to cross the occlusion. To another interesting topic Laina A et al. [28] discuss the arrhythmic risk of patients with mild left ventricle systolic impairment and the need to better stratified this underrepresented population in large randomized studies. Specifically, they argue on the need to screened patients with mild left ventricle impairment with a series of non-invasive tests which when examined may reveal a vulnerable population [29, 30] . • Myocardial cells infection causing myocardial injury • Myocardial infiltration by activated T-cells and Macrophages causing myocarditis • Infection of smooth muscle cells and pericytes causing microvascular and macrovascular impairment • Cytokine storm exacerbating inflammatory milieu and causing atherosclerosis progression and progress of stable atherosclerotic plaques to vulnerable • Blood deoxynation causing oxygen supply/demand inbalance and myocardial ischemia • All the aferomentionem mechanims can cause heart failure World Health Organization. Novel Coronavirus -China Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic WHO Director-General's opening remarks at the media briefing onCOVID-19 The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China GLP-1 receptor agonists and cardiovascular outcome trials: An update Cardiovascular disease in Greece; the latest evidence on risk factors Do we need biomarkers for diabetics progressing to heart failure? Patients with diabetes also deserve TAVR Population ageing and cardiovascular health: the case of Greece Association of hemoglobin A1c variability and the incidence of heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus and arterial hypertension Effect of diabetes mellitus on clinical outcomes and quality of life after transcatheter aortic valve implantation for severe aortic valve stenosis Prevalence of diabetes mellitus as well as cardiac and other main comorbidities in a representative sample of the adult Greek population in comparison with the general population The importance of left heart disease as a cause of pulmonary hypertension in COPD Balloon atrial septostomy in severe precapillary pulmonary hypertension: A single-center experience Chronic thromboembolic pulmonary hypertension. What we are missing? Detection and treatment of chronic thromboembolic pulmonary hypertension: Still a lot of homework to do The contribution of left heart disease in COPD patients with pulmonary hypertension Clinical diagnostic value of circulating serum miR-509-3p in pulmonary arterial hypertension with congenital heart disease Right ventricular involvement in hypertrophic cardiomyopathy: Patterns and implications Upgrade to cardiac resynchronization therapy difibrillator device of a pacemaker-dependent patient with end-stage hypertrophic cardiomyopathy Recurrent atherosclerosis complications as a mechanism for stent failure Laser-assisted orbital or rotational atherectomy: a hybrid treatment strategy for balloon-uncrossable lesions Considerations in selecting the appropriate implantable device in post-myocardial infarction syncopal patients with mild systolic dysfunction Arrhythmic risk stratification in nonischemic dilated cardiomyopathy: The ReCONSIDER study design -A two-step, multifactorial, electrophysiology-inclusive approach Reconsidering arrhythmic risk stratification in dilated cardiomyopathy -Beyond ventricular contractility and gene mutability